Cannabis as a substitute for prescription drugs - a cross-sectional study

被引:158
|
作者
Corroon, James M., Jr. [1 ]
Mischley, Laurie K. [2 ]
Sexton, Michelle [3 ]
机构
[1] Ctr Med Cannabis Educ, 428 8th St, Del Mar, CA 92014 USA
[2] Bastyr Univ, Res Inst, Kenmore, WA USA
[3] Ctr Study Cannabis & Social Policy, Dept Med Res, Seattle, WA USA
来源
JOURNAL OF PAIN RESEARCH | 2017年 / 10卷
关键词
cannabis; marijuana; prescription drugs; pain; analgesics; opioid; PATIENT-REPORTED OUTCOMES; MEDICAL CANNABIS; CHRONIC PAIN; SEX-DIFFERENCES; MENTAL-HEALTH; MARIJUANA; OPIOIDS; SUBSTANCES; EXPOSURE; ALCOHOL;
D O I
10.2147/JPR.S134330
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The use of medical cannabis is increasing, most commonly for pain, anxiety and depression. Emerging data suggest that use and abuse of prescription drugs may be decreasing in states where medical cannabis is legal. The aim of this study was to survey cannabis users to determine whether they had intentionally substituted cannabis for prescription drugs. Methods: A total of 2,774 individuals were a self-selected convenience sample who reported having used cannabis at least once in the previous 90 days. Subjects were surveyed via an online anonymous questionnaire on cannabis substitution effects. Participants were recruited through social media and cannabis dispensaries in Washington State. Results: A total of 1,248 (46%) respondents reported using cannabis as a substitute for prescription drugs. The most common classes of drugs substituted were narcotics/opioids (35.8%), anxiolytics/benzodiazepines (13.6%) and antidepressants (12.7%). A total of 2,473 substitutions were reported or approximately two drug substitutions per affirmative respondent. The odds of reporting substituting were 4.59 (95% confidence interval [CI], 3.87-5.43) greater among medical cannabis users compared with non-medical users and 1.66 (95% CI, 1.27-2.16) greater among those reporting use for managing the comorbidities of pain, anxiety and depression. A slightly higher percentage of those who reported substituting resided in states where medical cannabis was legal at the time of the survey (47% vs. 45%, p=0.58), but this difference was not statistically significant. Discussion: These patient-reported outcomes support prior research that individuals are using cannabis as a substitute for prescription drugs, particularly, narcotics/opioids, and independent of whether they identify themselves as medical or non-medical users. This is especially true if they suffer from pain, anxiety and depression. Additionally, this study suggests that state laws allowing access to, and use of, medical cannabis may not be influencing individual decision-making in this area.
引用
收藏
页码:989 / 997
页数:9
相关论文
共 50 条
  • [31] Prescription patterns and dosages of antiepileptic drugs in prevalent patients with epilepsy in Taiwan: A nationwide retrospective cross-sectional study
    Liang, Chun-Yu
    Chiang, Kuo-Liang
    Hsieh, Liang-Po
    Chien, Li-Nien
    EPILEPSY & BEHAVIOR, 2022, 126
  • [32] Prevalence and nature of manufacturer-sponsored patient support programs for prescription drugs in Canada: a cross-sectional study
    Grundy, Quinn
    Quanbury, Ashton
    Hart, Dana
    Chaudhry, Shanzeh
    Tavangar, Farideh
    Lexchin, Joel
    Gagnon, Marc-Andre
    Tadrous, Mina
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2023, 195 (46) : E1565 - E1576
  • [33] A Cross-Sectional Survey Study of Cannabis Use for Fibromyalgia Symptom Management
    Singla, Abhinav
    Anstine, Christopher V.
    Huang, Linda
    Rosedahl, Jordan K.
    Mohabbat, Arya B.
    Philpot, Lindsey M.
    MAYO CLINIC PROCEEDINGS, 2024, 99 (04) : 542 - 550
  • [34] Use of Medical Cannabis by Patients with Fibromyalgia: A Prospective Cross-sectional Study
    Fitzcharles, Mary-Ann
    Rampakakis, Emmanouil
    Shir, Yoram
    Sampalis, John
    Cohen, Martin
    Starr, Michael
    Haeuser, Winfried
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [35] Use of cannabis for mental health in the Canadian territories: a cross-sectional study
    Schwartz, Naomi
    Poon, Theresa
    Hammond, David
    Hobin, Erin
    SUBSTANCE USE & MISUSE, 2025, 60 (01) : 74 - 82
  • [36] Informing the cannabis policy debate: a cross-sectional study of current and former cannabis users in Ireland
    James, Philip D.
    Comiskey, Catherine M.
    JOURNAL OF SUBSTANCE USE, 2024,
  • [37] Use of medical cannabis by patients with fibromyalgia in Canada after cannabis legalisation: a cross-sectional study
    Fitzcharles, M-A
    Rampakakis, E.
    Sampalis, J.
    Shir, Y.
    Cohen, M.
    Starr, M.
    Hauser, W.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (03) : S115 - S119
  • [38] Prescription-free consultation: A cross-sectional study in general practice
    Richard, Amelie
    Charuel, Elodie
    Cambier, Sebastien
    Turpin, Manon
    Baudin, Bruno
    Moreno, Jose-Philippe
    Vaillant-Roussel, Helene
    THERAPIE, 2024, 79 (03): : 319 - 326
  • [39] Prescription of medicines by medical students of Karachi, Pakistan: A cross-sectional study
    Syed Nabeel Zafar
    Reema Syed
    Sana Waqar
    Faria A Irani
    Sarah Saleem
    BMC Public Health, 8
  • [40] Use of delayed antibiotic prescription in primary care: a cross-sectional study
    Mariam de la Poza Abad
    Gemma Mas Dalmau
    Ignasi Gich Saladich
    Laura Martínez García
    Carl Llor
    Pablo Alonso-Coello
    BMC Family Practice, 20